FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 3879-3890

  Li, Shuying S ^a   Gilbert, Peter B ^a   Tomaras, Georgia D ^b   Kijak, Gustavo ^c   Ferrari, Guido ^b   Thomas, Rasmi ^c   Pyo, Chul Woo ^a   Zolla Pazner, Susan ^d   Montefiori, David ^b   Liao, Hua Xin ^b   Nabel, Gary ^e   Pinter, Abraham ^f   Evans, David T ^g   Gottardo, Raphael ^a   Dai, James Y ^a   Janes, Holly ^a   Morris, Daryl ^a   Fong, Youyi ^a   Edlefsen, Paul T ^a   Li, Fusheng ^a   Frahm, Nicole ^a   Alpert, Michael D ^h   Prentice, Heather ^c   Rerks Ngarm, Supachai ⁱ   Pitisuttithum, Punnee ^j   Kaewkungwal, Jaranit ^j   Nitayaphan, Sorachai ^k   Robb, Merlin L ^c   O'Connell, Robert J ^c   Haynes, Barton F ^b   Michael, Nelson L ^c   Kim, Jerome H ^c   McElrath, M Juliana ^a   Geraghty, Daniel E ^a   more..

^a USA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Sanofi   (United States)

^f PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MINISTRY OF PUBLIC HEALTH   (Thailand)

^j MAHIDOL UNIVERSITY   (Thailand)

^k Royal Thai Army   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; LYSINE; FC GAMMA RECEPTOR IIC; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NONHUMAN; PHASE 3 CLINICAL TRIAL; POSITION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; GENOTYPE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; VACCINATION;

EID: 84907014639     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75539     Document Type: Article

References (53)

1. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
2. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-1286.
3. Zolla-Pazner S, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/ AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013;8(1):e53629.
4. Zolla-Pazner S, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9(2):e87572.
5. Tomaras GD, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013;110(22):9019-9024.
6. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
7. Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105-125.
8. Karassa FB, Trikalinos TA, Ioannidis JP. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother. 2004;58(5):286-291.
9. Nimmerjahn F. Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin Immunopathol. 2006;28(4):305-319.
10. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007;179(11):7916-7923.
11. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178(10):6596-6603.
12. Poonia B, Kijak GH, Pauza CD. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One. 2010;5(12):e15562.
13. Pandey JP, Namboodiri AM, Bu S, De Dieu Tapsoba J, Sato A, Dai JY. Immunoglobulin genes and the acquisition of HIV infection in a randomized trial of recombinant adenovirus HIV vaccine. Virology. 2013;441(1):70-74.
14. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30(1):25-28.
15. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012;120(14):2836-2842.
16. Concetti F, Napolioni V. Insights into the role of Fc gamma receptors (FcγRs) genetic variations in monoclonal antibody-based anti-cancer therapy. Recent Pat Anticancer Drug Discov. 2010;5(3):197-204.
17. Adu B, et al. Fc gamma receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children. PLoS One. 2012;7(9):e46197.
18. Gomes MM, Herr AB. IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential. Springer Semin Immunopathol. 2006;28(4):383-395.
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265.
20. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet. 2005;37(11):1217-1223.
21. Dai JY, Li SS, Gilbert PB. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics. Biostatistics. 2014;15(1):196-203.
22. Rolland M, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490(7420):417-420.
23. Liao HX, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38(1):176-186.
24. Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcγRIIC gene. Blood. 1998;91(7):2369-2380.
25. Robb ML, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12(7):531-537.
26. Yates NL, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239.
27. Bruhns P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725.
28. Bonsignori M, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012;86(21):11521-11532.
29. Warmerdam PA, Nabben NM, van de Graaf SA, van de Winkel JG, Capel PJ. The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem. 1993;268(10):7346-7349.
30. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol. 2012;188(3):1318-1324.
31. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells. J Mol Med (Berl). 2002;80(4):248-257.
32. Breunis WB, et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C, and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat. 2009;30(5):E640-E650.
33. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: A specific role for antibodies against the membrane-proximal external region of gp41. J Virol. 2009;83(15):7397-7410.
34. Genomes Project C, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65.
35. Espeli M, Niederer HA, Traherne JA, Trowsdale J, Smith KG. Genetic variation, Fcγ receptors, KIRs and infection: the evolution of autoimmunity. Curr Opin Immunol. 2010;22(6):715-722.
36. Cassel DL, et al. Differential expression of FcγRIIA, FcγRIIB, and FcγRIIC in hematopoietic cells: analysis of transcripts. Mol Immunol. 1993;30(5):451-460.
37. Lehmann B, Schwab I, Bohm S, Lux A, Biburger M, Nimmerjahn F. FcγRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol. 2012;8(3):243-254.
38. Chung AW, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014;6(228):228ra238.
39. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615-1617.
40. Siber GR. Methods for estimating serological correlates of protection. Dev Biol Stand. 1997;89:283-296.
41. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med. 2005; 11(4 suppl):S54-S62.
42. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401-409.
43. Shea PR, Shianna KV, Carrington M, Goldstein DB. Host genetics of HIV acquisition and viral control. Annu Rev Med. 2013;64:203-217.
44. Carrington M, Walker BD. Immunogenetics of spontaneous control of HIV. Annu Rev Med. 2012;63:131-145.
45. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo- controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-1893.
46. Duerr A, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012;206(2):258-266.
47. Hammer SM, et al. Efficacy trial of a DNA/ rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083-2092.
48. Smith WP, Vu Q, Li SS, Hansen JA, Zhao LP, Geraghty DE. Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics. 2006;87(5):561-571.
49. Vittinghoff E, Bauer DC. Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics. 2006;62(3):769-776.
50. Dai JY, Kooperberg C, LeBlanc M, Prentice RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. Biometrika. 2010;94(4):1-16.
51. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. Hoboken, New Jersey, USA: John Wiley and Sons; 1993.
52. Breslow NE, Holubkov R. Maximum likelihood estimation of logistic regression parameters for two-phase outcome-dependent sampling. J R Statist Soc. 1997;59B:447-461.
53. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological). 1995;57:289-300.